PT - JOURNAL ARTICLE AU - Cheng, Xingxing AU - Feng, Yong AU - Chen, Sai AU - Zhang, Han AU - Chen, Ruiping AU - Xu, Bo AU - Hu, Xiao AU - Wei, Wei AU - Chen, Zhenguang AU - Geng, Qian AU - Wang, Junqi TI - Rapid Point-of-Care Exhaled Breath Analysis for Lung Cancer Diagnosis Using a Micro Gas Chromatography System: A Pilot Study AID - 10.1101/2024.06.27.24309565 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.27.24309565 4099 - http://medrxiv.org/content/early/2024/06/27/2024.06.27.24309565.short 4100 - http://medrxiv.org/content/early/2024/06/27/2024.06.27.24309565.full AB - The study investigates the use of volatile organic compounds (VOCs) in exhaled breath as a non-invasive diagnostic tool for lung cancer (LC). Employing a novel micro gas chromatography-micro photoionisation detector (μGC-μPID) system, we aimed to identify and validate VOCs that could differentiate between LC patients and those with benign pulmonary diseases. The cross-sectional study included 106 participants, categorized into 85 LC patients and 21 benign controls, based on computed tomography and histological assessments. Participants provided breath samples following a standardized protocol, and the μGC-μPID system, known for its rapid point-of-care capabilities and low detection limits, was utilized for rapid and sensitive online VOC analysis. Through a meticulous process of data analysis, including principal component analysis, single-factor hypothesis testing, orthogonal partial least squares discriminant analysis and various tests of machine learning algorithms, including random forest, k-nearest neighbor, logistic regression, XGBoost, and support vector machine, we finally identified six potential VOC biomarkers, with diagnostic models incorporating these markers achieving high sensitivity (0.95-1.00) and specificity (0.84-0.88), and areas under the receiver operating characteristic curve ranging from 0.79 to 0.91. Moreover, these models were also extended favourably to the recurrence and metastasis of pulmonary cancer and oesophageal cancer. The study demonstrates the potential of μGC-μPID as a point-of-care tool for LC differential diagnosis, highlighting the need for further validation in larger, multi-centric cohorts to refine the VOC biomarker panel and establish a robust diagnostic framework for clinical application.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was not supported by any grants.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData sharing is not applicable to this article as no datasets were generated or analyzed during the current study.